- Home
- MHF vs CRBP Comparison
MHF vs CRBP Comparison
Compare MHF & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MHF | CRBP |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.4M | 147.4M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | MHF | CRBP |
|---|---|---|
| Price | $6.78 | $10.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.60 |
| AVG Volume (30 Days) | 58.0K | ★ 244.4K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 4.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $6.61 | $6.10 |
| 52 Week High | $7.64 | $20.56 |
Technical Indicators
Market Signals| Indicator | MHF | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 51.57 |
| Support Level | $6.72 | $9.86 |
| Resistance Level | $7.00 | $10.74 |
| Average True Range (ATR) | 0.09 | 0.64 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 0.00 | 25.00 |
Price Performance
Historical ComparisonAbout MHF Western Asset Municipal High Income Fund Inc.
Western Asset Municipal High Income Fund Inc is a diversified closed-end management investment company. The company's objective is to seek high current income exempt from federal income taxes. It invests predominantly in intermediate and long-term municipal debt securities issued by state and local governments.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.